Frontier Wealth Management LLC Acquires Shares of 1,384 Allergan PLC. (NYSE:AGN)

Frontier Wealth Management LLC acquired a new position in shares of Allergan PLC. (NYSE:AGN) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,384 shares of the company’s stock, valued at approximately $336,000.

A number of other hedge funds have also recently modified their holdings of AGN. Howard Hughes Medical Institute purchased a new position in Allergan PLC. during the second quarter worth $103,000. Jacobi Capital Management LLC increased its position in Allergan PLC. by 4.9% during the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after buying an additional 22 shares in the last quarter. JNBA Financial Advisors increased its position in Allergan PLC. by 2.5% during the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after buying an additional 12 shares in the last quarter. Massey Quick & Co. LLC grew its position in shares of Allergan PLC. by 334.8% in the second quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock valued at $122,000 after purchasing an additional 385 shares during the period. Finally, Pacific Center for Financial Services grew its position in shares of Allergan PLC. by 805.1% in the first quarter. Pacific Center for Financial Services now owns 534 shares of the company’s stock valued at $128,000 after purchasing an additional 475 shares during the period. 81.94% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages have recently commented on AGN. Vetr raised Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 price objective for the company in a research report on Monday, June 26th. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $280.00 price objective (up previously from $270.00) on shares of Allergan PLC. in a research report on Wednesday, August 9th. UBS AG set a $255.00 price objective on Allergan PLC. and gave the company a “buy” rating in a research report on Tuesday. Deutsche Bank AG set a $251.00 target price on Allergan PLC. and gave the company a “buy” rating in a report on Tuesday. Finally, Credit Suisse Group set a $243.00 target price on Allergan PLC. and gave the company an “outperform” rating in a report on Tuesday. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $266.69.

Allergan PLC. (NYSE:AGN) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The firm had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. During the same period in the prior year, the company posted $3.35 EPS. The company’s revenue was up 8.8% on a year-over-year basis.

Allergan PLC. declared that its Board of Directors has initiated a stock buyback plan on Monday, September 25th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to purchase up to 2.8% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its stock is undervalued.

TRADEMARK VIOLATION NOTICE: “Frontier Wealth Management LLC Acquires Shares of 1,384 Allergan PLC. (NYSE:AGN)” was reported by BBNS and is the property of of BBNS. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://baseballnewssource.com/markets/1384-shares-in-allergan-plc-agn-acquired-by-frontier-wealth-management-llc/1701830.html.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with our FREE daily email newsletter.

 


Latest News

Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation


Leave a Reply

 
© 2006-2017 BBNS.